The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. - Test2 - elhamkhani - TriplyDB

The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.

The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.

http://www.wikidata.org/entity/Q34857971

about

Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Anti-inflammatory therapies for cardiovascular disease Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Ageing induced vascular smooth muscle cell senescence in atherosclerosis.Effect of testosterone deficiency on cholesterol metabolism in pigs fed a high-fat and high-cholesterol diet.Sirtuins, aging, and cardiovascular risks.Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs.Protective effects of sirtuins in cardiovascular diseases: from bench to bedside Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.Sirtuins, Cell Senescence, and Vascular Aging SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway SIRT6 protects against endothelial dysfunction and atherosclerosis in mice Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.SIRT1 and SIRT6 Signaling Pathways in Cardiovascular Disease Protection.The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice.The Mechanism of Diabetic Retinopathy Pathogenesis Unifying Key Lipid Regulators, Sirtuin 1 and Liver X Receptor.SIRT1 inhibition promotes atherosclerosis through impaired autophagy.The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways.SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury.

P2860

Q28314993-2EDBB15E-04EF-4169-878B-D93E4A144385 Q30381121-AAC483C6-B8B7-4EA4-AF1C-3D9E973E2B1F Q33599961-BB3EAF7F-A737-4DD3-9D98-77AA9BC2737B Q34137872-38713E7D-1ED7-4F58-982B-413E6EF6D83E Q34458693-A6B3DF80-B50D-4431-983B-B06A38A49453 Q34485057-D18108CA-4EF5-4836-969F-D9C0149BA453 Q35170131-B2C299D1-A8D0-48B3-9E0D-CA473EDA2682 Q35768345-093BDEF5-BC12-45AF-A405-A9870016ED14 Q36107283-E2A66499-FBCE-4F37-A430-AA5484B0491F Q36387714-ED2AC583-1CB5-4ADD-B273-47B7B9CBAC15 Q36506609-2F7D86E7-A312-4CE1-A6D1-F398E19C5D39 Q36844727-458EF831-9003-40DA-845D-E4843636D0FA Q36901972-EF0E99FA-9883-406B-9C2E-DAA46F55E9B6 Q37062509-C8F31D1B-445E-4362-A612-0F341C061323 Q37688760-57A97652-1721-4085-A440-75A98132A6CC Q38665115-8861495F-9D14-4CC3-85B7-461D8661A176 Q40866536-68273AEA-011B-468C-AC7C-E4D971AEF720 Q41348534-C533BC13-B785-4EA6-AD47-E62B0E10986B Q41612831-95CEB6CA-5655-4038-B1D1-96846BC75D62 Q41632623-DE949702-3F63-4939-9D3B-9A18A177AC4E Q50892176-0CD1DD91-A19D-4429-8682-9D9317645609 Q51301800-622A8E14-0C9E-4803-B16E-0E9A826C0F55

P2860

The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.

http://www.wikidata.org/entity/Q34857971

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@ast

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@en

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@nl

type

label

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@ast

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@en

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@nl

altLabel

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression

@en

prefLabel

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@ast

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@en

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@nl

P1433

Q34857971-06C3F296-0803-4EAB-ABAA-8FC94E924302

P1476

Q34857971-50AF29CE-760C-4934-91D9-DA88D4BB1A28

P2093

Q34857971-14758E2B-DC29-466E-BA6D-DD8E9C1DD118

Q34857971-3A43FC2F-D54C-4CB4-89AF-E5C0A635BD10

Q34857971-4ED2E83E-03CB-4CA1-8381-5947A263619F

Q34857971-69D4C506-7525-4B15-A8E3-F7A7A3DF9E55

Q34857971-6B159E43-28E0-4FE2-A30C-82C073A6E429

Q34857971-A872DDF7-D5D8-4200-B6D1-4CCEEEF8D843

Q34857971-C73C077F-B363-4832-80CD-3A091491CD10

Q34857971-CB5CDE96-FA2C-4752-B2F1-E2CE39556371

Q34857971-D2823D52-75D0-4BD6-846A-C1C56D1E85BA

P2860

Q34857971-010070F8-A53E-4853-A7D4-A2C091CD5CBD

Q34857971-106F9EE3-3A60-4F9A-9753-F3DAE958FA75

Q34857971-111C2C3E-C658-43FD-A10C-653F4DC5680A

Q34857971-190BA03C-8D84-471B-A487-4A42EB2B0614

Q34857971-1A7CA475-339A-48EF-A2E2-2D1F2CF8A500

Q34857971-1DB4B7F0-9289-484F-B379-1E906DC6CFEE

Q34857971-1FD39DC6-9D03-4749-B523-C73AB4E1E049

Q34857971-22ADC129-9C22-4AEF-AFF0-9A67E28C5AF8

Q34857971-26AF7748-4984-40ED-8252-656DE9E29060

Q34857971-29D6E914-8FA9-416D-A1B5-AB48D10E3B34

P304

Q34857971-AC8E2F2D-60F3-4CA9-85F2-F6AA78E3D034

P31

Q34857971-E85A471A-DF0A-4BBD-9217-3BC1C07E5326

P356

Q34857971-DA4F69A6-91F2-4F7C-8D2F-31B2FC4C2D43

P433

Q34857971-DA9C1D71-4AF9-4541-8060-6B103E75B4A5

P478

Q34857971-411AB810-40E1-48A5-A66A-223F1CCEAC3C

P50

Q34857971-140463D1-C80A-456C-B3D0-E22788CE1164

Q34857971-192BE986-1979-4D1D-9270-2F09330B4310

Q34857971-1BA35DD8-36C0-4E40-9365-21F0873B123E

Q34857971-1D054635-5EEA-4165-91EB-EE6950BACB56

Q34857971-55EB74BB-1BAF-4B04-8578-55D87BB99BF9

Q34857971-6B3A7EFA-B1E4-42F9-B88C-07BB340DC444

Q34857971-99FAC366-64CE-4CE9-BB73-8D56F1034B4C

Q34857971-BD94B7FF-15B2-4923-8252-7579EE907E03

Q34857971-C807DADD-B35A-4ED1-A91F-A6A0EEDD26D2

P577

Q34857971-540CA614-FDDA-4254-AB8E-BA6B2DC48A5F

P5875

Q34857971-1E6141BD-029B-4A75-90E0-96D269DCC67B

P698

Q34857971-813C79E4-093F-4CA8-BEFA-29D80554E599

P932

Q34857971-1415F890-0D66-4A45-9EC4-2244942E346B

P356

P1433

European Heart Journal

P1476

The Sirt1 activator SRT3025 pr ...... and enhancing Ldlr expression.

@en

P2093

Ana P Gomes

http://www.w3.org/2001/XMLSchema#string

Christian M Matter

http://www.w3.org/2001/XMLSchema#string

Christine Lohmann

http://www.w3.org/2001/XMLSchema#string

David A Sinclair

http://www.w3.org/2001/XMLSchema#string

James L Ellis

http://www.w3.org/2001/XMLSchema#string

Lambertus J van Tits

http://www.w3.org/2001/XMLSchema#string

Melroy X Miranda

http://www.w3.org/2001/XMLSchema#string

Tasneem Arsiwala

http://www.w3.org/2001/XMLSchema#string

Vipin Suri

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime

Evidence for a common mechanism of SIRT1 regulation by allosteric activators

Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia

Proatherogenic abnormalities of lipid metabolism in SirT1 transgenic mice are mediated through Creb deacetylation

The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells

Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery

P304

51-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHU095

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Kristina Schoonjans

Michael O Hottiger

Thomas Lüscher

P577

2014-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260610399

http://www.w3.org/2001/XMLSchema#string

P698

24603306

http://www.w3.org/2001/XMLSchema#string

P932

4286317

http://www.w3.org/2001/XMLSchema#string